18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions

Jonsson Comprehensive Cancer Center

Status: Terminated

Conditions: Malignant Neoplasm

Treatments: Procedure: Positron Emission Tomography; Radiation: Fluorine F 18 Clofarabine; Procedure: Computed Tomography

Study type: Observational

Funder types: Other

Identifiers

NCT02888301

15-000246 (Other Identifier)

NCI-2016-00210 (Registry Identifier)

Details and patient eligibility

About

This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed tomography (CT) in imaging patients with cancer before and after treatment with a therapy that activates the patient's immune system (immunotherapy). PET/CT scans give detailed pictures of areas inside the body. 18F-clofarabine is a drug that contains a radioactive substance that is taken up by cells expressing deoxycytidine kinase (dCK), which is highly expressed in activated immune cells, making them light up during PET/CT scans. Doctors also want to know how 18F-clofarabine is distributed throughout the body before and after treatment with immunotherapies.

Full description

PRIMARY OBJECTIVES:

I. To determine whether positron emission tomography (PET) using the new imaging agent 18F-clofarabine can be used for imaging cancer, and whether interventions that activate the immune system can change the biodistribution of 18F-clofarabine.

OUTLINE:

Patients receive 18F-clofarabine intravenously (IV) and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine)
• No restrictions based on gender or racial/ethnic background

Exclusion criteria

• Women of childbearing age will have to undergo a pregnancy test that will be provided free of charge

Trial design

12 participants in 1 patient group

Basic science (18F-clofarabine biodistribution)

Description:

Patients receive 18F-clofarabine IV and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.

Treatment:

Procedure: Computed Tomography

Procedure: Positron Emission Tomography

Radiation: Fluorine F 18 Clofarabine